Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05820191
PHASE2

B-amyloid as a Marker for GBM Bioimaging

Sponsor: Universidad Central del Caribe

View on ClinicalTrials.gov

Summary

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will provide data for development of new approach for GBM diagnostics.

Key Details

Gender

All

Age Range

21 Years - Any

Study Type

INTERVENTIONAL

Enrollment

3

Start Date

2024-07

Completion Date

2026-07

Last Updated

2023-12-21

Healthy Volunteers

No

Conditions

Interventions

DRUG

Amyvid, Intravenous Solution

Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.

Locations (2)

Central University of the Caribbean (UCC)

Bayamón, PR, Puerto Rico

University of Puerto Rico, Medical Science Campus

San Juan, Puerto Rico